Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.77 |
| ▸ | ITGB3 | P05106 | 17/20 | 0.77 |
| ▸ | ITGB6 | P18564 | 7/20 | 0.58 |
| ▸ | ITGB8 | P26012 | 6/20 | 0.58 |
| ▸ | ITGB5 | P18084 | 4/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5256976 | 1.00 | ITGAV (0.77) | ITGAVITGB3ITGB6ITGB8ITGB5 | |
| SCHEMBL5254158 | 1.00 | ITGAV (0.77) | ITGAVITGB3ITGB6ITGB8ITGB5 | |
| SCHEMBL7433549 | 0.97 | ITGAV (0.81) | ITGAVITGB3ITGB6ITGB8ITGB5 | |
| SCHEMBL7436110 | 0.97 | ITGAV (0.81) | ITGAVITGB3ITGB6ITGB8ITGB5 | |
| SCHEMBL7437194 | 0.97 | ITGAV (0.81) | ITGAVITGB3ITGB6ITGB8ITGB5 | |
| SCHEMBL14380623 | 0.94 | ITGAV (0.73) | ITGAVITGB3ITGB6ITGB8ITGB5 | |
| SCHEMBL5255745 | 0.93 | ITGAV (0.66) | ITGAVITGB3ITGB6ITGB8ITGB5 | |
| SCHEMBL5255108 | 0.93 | ITGAV (0.66) | ITGAVITGB3ITGB6ITGB8ITGB5 | |
| SCHEMBL5255148 | 0.93 | ITGAV (0.66) | ITGAVITGB3ITGB6ITGB8ITGB5 | |
| SCHEMBL5254905 | 0.91 | ITGAV (0.76) | ITGAVITGB3ITGB6ITGB8ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1187592-B1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2007-08-01 | — | — | EP | claimed |
| EP-1187592-A4 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2002-11-06 | — | — | EP | claimed |
| US-6410526-B1 | BONE DISORDERS; RESTENOSIS; VISION DISORDERS; ANTICHOLESTEROL AGENTS; ANTICANCER, ANTITUMOR AGENTS | MERCK & CO., INC. | 2002-06-25 | — | — | US | claimed |
| EP-1187592-A2 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2002-03-20 | — | — | EP | claimed |
| WO-2000072801-A2 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-12-07 | — | — | WO | claimed |
| US-20190307735-A1 | Composition and Methods for Treating Chronic Kidney Disease | MERCK SHARP & DOHME CORP (US) | 2019-10-10 | — | — | US | disclosed |
| US-20190307735-A1 | Composition and Methods for Treating Chronic Kidney Disease | MERCK SHARP & DOHME CORP (US) | 2019-10-10 | — | — | US | disclosed |
| WO-2016154369-A1 | COMPOSITION AND METHODS FOR TREATING CHRONIC KIDNEY DISEASE | MERCK SHARP & DOHME CORP. (US) | 2016-09-29 | — | — | WO | disclosed |
| US-7288655-B2 | α v integrin receptor antagonists | MERCK & CO., INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-7288655-B2 | α v integrin receptor antagonists | MERCK & CO., INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-7288655-B2 | α v integrin receptor antagonists | MERCK & CO., INC. (US) | 2007-10-30 | — | — | US | disclosed |
| EP-1187592-B1 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20060149069-A1 | Process for synthesising useful intermediates for the preparation of avss3 receptor antagonists | MERCK SHARP & DOHME LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| US-20050101593-A1 | Phosphoric acid salt of an integrin receptor antagonist | MEISSNER ROBERT S (US) | 2005-05-12 | — | — | US | disclosed |
| EP-1326615-A1 | PHOSPHORIC ACID SALT OF AN INTEGRIN RECEPTOR ANTAGONIST | Merck & Co., Inc. (US) | 2003-07-16 | — | — | EP | disclosed |
| EP-1187592-A4 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2002-11-06 | — | — | EP | disclosed |
| US-6410526-B1 | BONE DISORDERS; RESTENOSIS; VISION DISORDERS; ANTICHOLESTEROL AGENTS; ANTICANCER, ANTITUMOR AGENTS | MERCK & CO., INC. | 2002-06-25 | — | — | US | disclosed |
| WO-2002028395-A1 | PHOSPHORIC ACID SALT OF AN INTEGRIN RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 2002-04-11 | — | — | WO | disclosed |
| EP-1187592-A2 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000072801-A2 | ALPHA V INTEGRIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190307735-A1 | Composition and Methods for Treating Chronic Kidney Disease | ITGAM, ITGB1, ITGB2 | ITGAV 5/4885ITGB3 9/4885ITGB6 24/4885 |
| US-20060149069-A1 | Process for synthesising useful intermediates for the preparation of avss3 receptor antagonists | AVPR1A, AVPR1B, ADRB3 | ITGAV 484/4885ITGB3 94/4885ITGB6 1033/4885 |
| US-20050101593-A1 | Phosphoric acid salt of an integrin receptor antagonist | ITGA5, ITGAL, ITGA2 | ITGAV 12/4885ITGB3 5/4885ITGB6 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.